Details for New Drug Application (NDA): 021231
✉ Email this page to a colleague
The generic ingredient in ZOMIG-ZMT is zolmitriptan. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.
Summary for 021231
Tradename: | ZOMIG-ZMT |
Applicant: | Astrazeneca |
Ingredient: | zolmitriptan |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 2.5MG | ||||
Approval Date: | Feb 13, 2001 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 5MG | ||||
Approval Date: | Sep 17, 2001 | TE: | RLD: | Yes |
Expired US Patents for NDA 021231
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astrazeneca | ZOMIG-ZMT | zolmitriptan | TABLET, ORALLY DISINTEGRATING;ORAL | 021231-001 | Feb 13, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
Astrazeneca | ZOMIG-ZMT | zolmitriptan | TABLET, ORALLY DISINTEGRATING;ORAL | 021231-002 | Sep 17, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription